The hyper-CVAD regimen in adult acute lymphocytic leukema

被引：49

作者：

Garcia-Manero, G

Kantarjian, HM

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas, Sch Med, Div Oncol, Houston, TX USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2000年 / 14卷 / 06期

关键词：

D O I：

10.1016/S0889-8588(05)70192-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The regimen of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) has demonstrated significant activity in adult lymphocytic leukemia (ALL) and in other hematologic malignancies, including Burkitt's disease, lymphoblastic lymphoma mantle cell lymphoma and multiple myeloma. This article presents the rationale for the development of this regimen, describes the program, summarizes the results of the large clinical trials developed at the University of Texas M.D. Anderson Cancer Center, and discusses strategies to improve the results.

引用

收藏

页码：1381 / +

页数：18

相关论文

共 27 条

[1]

BAGLEY CM, 1973, CANCER RES, V33, P226

[2] THE MORPHOLOGICAL CLASSIFICATION OF ACUTE LYMPHOBLASTIC-LEUKEMIA - CONCORDANCE AMONG OBSERVERS AND CLINICAL CORRELATIONS [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1981, 47 (04) :553-+

[3]

Beran M, 1998, CLIN CANCER RES, V4, P1661

[4] THE VALUE OF HIGH-DOSE SYSTEMIC CHEMOTHERAPY AND INTRATHECAL THERAPY FOR CENTRAL-NERVOUS-SYSTEM PROPHYLAXIS IN DIFFERENT RISK GROUPS OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA [J].

CORTES, J ;

OBRIEN, SM ;

PIERCE, S ;

KEATING, MJ ;

FREIREICH, EJ ;

KANTARJIAN, HM .

BLOOD, 1995, 86 (06) :2091-2097

[5]

Druker BJ, 1999, BLOOD, V94, p697A

[6]

Dyer MJS, 1999, SEMIN ONCOL, V26, P52

[7] Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy [J].

Estey, E ;

Thall, P ;

Beran, M ;

Kantarjian, H ;

Pierce, S ;

Keating, M .

BLOOD, 1997, 90 (08) :2969-2977

[8] Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia [J].

Faderl, S ;

Kantarjian, HM ;

Thomas, DA ;

Cortes, J ;

Giles, F ;

Pierce, S ;

Albitar, M ;

Estrov, Z .

LEUKEMIA & LYMPHOMA, 2000, 36 (3-4) :263-273

[9] Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response [J].

Gandhi, V ;

Plunkett, W ;

Rodriguez, CO ;

Nowak, BJ ;

Du, M ;

Ayres, M ;

Kisor, DF ;

Mitchell, BS ;

Kurtzberg, J ;

Keating, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3607-3615

[10] A CAUSE-SPECIFIC HAZARD RATE ANALYSIS OF PROGNOSTIC FACTORS AMONG 199 ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - THE MEMORIAL HOSPITAL EXPERIENCE SINCE 1969 [J].

GAYNOR, J ;

CHAPMAN, D ;

LITTLE, C ;

MCKENZIE, S ;

MILLER, W ;

ANDREEFF, M ;

ARLIN, Z ;

BERMAN, E ;

KEMPIN, S ;

GEE, T ;

CLARKSON, B .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :1014-1030